Calcium lactate gluconate with calcium carbonate oral
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Oral formulations of calcium lactate gluconate with calcium carbonate.
Drugs List
Therapeutic Indications
Uses
Calcium deficiency
Prophylaxis and treatment of calcium deficiency.
Calcium supplement as an adjunct to specific therapy in the prophylaxis and treatment of osteoporosis.
Rickets and osteomalacia, in addition to vitamin D3 therapy.
Dosage
Effervescent tablets containing calcium lactate gluconate 2.263g and calcium carbonate 1.75g (1g (25mmol) of calcium).
Adults
1 tablet daily.
Children
Children aged 10 to 18 years
1 tablet daily.
The following alternative dosing schedule may be suitable:
Calcium deficiency (unlicensed)
Children aged 12 to 18 years: 10mmol four times daily, titrated to response.
Children aged 5 to 12 years: 0.2mmol/kg four times daily, titrated to response.
Children aged 1 month to 5 years: 0.25mmol/kg four times daily, titrated to response.
Neonates
Calcium deficiency (unlicensed)
0.25mmol/kg four times a day. Titrate to response.
Contraindications
Hereditary fructose intolerance
Hypercalcaemia
Nephrocalcinosis
Nephrolithiasis
Phenylketonuria
Severe hypercalciuria
Precautions and Warnings
Children under 10 years
Glucose-galactose malabsorption syndrome
History of nephrolithiasis
Hypercalciuria
Renal impairment
Sarcoidosis
Contains aspartame - caution in phenylketonuria
Contains glucose
Presentations with sorbitol unsuitable in hereditary fructose intolerance
Monitor serum and urinary calcium in patients with sarcoidosis
Monitor serum calcium levels in patients with renal impairment
Monitor serum calcium on prolonged use or with high doses of vitamin D
Monitor serum phosphate levels in patients with renal impairment
Monitor urinary calcium in mild hypercalciuria
Monitor urinary calcium in patients with a history of renal stones
Each effervescent tablet contains 5.95mmol (136.90mg) of sodium.
Each effervescent tablet contains equivalent to 30mg per dose of phenylalanine.
Each effervescent tablet contains 630 micrograms of sorbitol.
Each effervescent tablet contains 210 nanograms of sulphur dioxide that may cause hypersensitivity reactions and bronchospasm.
An increased fluid intake is recommended in patients prone to formation of calculi.
Pregnancy and Lactation
Pregnancy
Calcium lactate gluconate with calcium carbonate is considered safe for use during pregnancy.
The manufacturer advises calcium lactate gluconate with calcium carbonate may be used safely during pregnancy.
Lactation
Calcium lactate gluconate with calcium carbonate is considered safe for use during breastfeeding.
The manufacturer advises calcium lactate gluconate with calcium carbonate may be used safely when breastfeeding.
Side Effects
Abdominal pain
Anaphylactic reaction
Angioneurotic oedema
Constipation
Diarrhoea
Facial oedema
Flatulence
Hypercalcaemia
Hypercalciuria
Hypersensitivity reactions
Nausea
Pruritus
Rash
Urticaria
Vomiting
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: June 2020
Reference Sources
Summary of Product Characteristics: Calvive 1000 Effervescent Tablets. GlaxoSmithKline Consumer Healthcare. Revised January 2020.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 04 June 2020
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.